Evaluation of cefazolin in the treatment of bacterial endocarditis and bacteremia.
D000328:Adult; D000368:Aged; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008837:Micrococcus / Q000187:drug effects; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013290:Streptococcal Infections; D013291:Streptococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013440:Sulfides / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D013830:Thiadiazoles / Q000627:therapeutic use
D002511:Cephalosporins; D013440:Sulfides; D013777:Tetrazoles; D013830:Thiadiazoles